Skip to content

Acute, Affective, Organic Disorders.

Signs of Organic Brain Dysfunction in Psychiatric Patients With Fluctuating Psychiatric Symptoms Including Brief Depressions Compared to Patients With a Major Depressive Episode.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00201474
Enrollment
32
Registered
2005-09-20
Start date
1998-10-31
Completion date
2010-06-30
Last updated
2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorders

Keywords

brief depressive episodes, affective disorders, EEG and QEEG, epilepsy, organic brain disorders, acute psychiatry

Brief summary

The purpose of the study is to investigate whether patients with brief depressive periods together with other fluctuating psychiatric symptoms, have this condition due to epilepsy or an other organic brain disorder.

Detailed description

A limited number of patients admitted to psychiatric acute wards or Psychiatric Intensive Care Units are admitted with a fluctuating array of psychiatric symptoms including brief depressive episodes. These patients do not fit into the present diagnostic systems due to short duration of affective symptoms and the fluctuating arrays of other symptoms. Case histories indicate that these patients have psychiatric conditions due to epilepsy or organic brain dysfunctions. In the study acutely admitted patients filling criteria for two recent DSM-4 axis 1 diagnoses (one is a brief depressive period) during the last two weeks are compared to age- and sex-matched patients acutely admitted with a major depressive disorder. The patients are rated with a number of rating scales at admittance, day 5, after two weeks and three months. EEG and QEEG are taken three times the first week. MRI, drug screening and blood screening of medication-concentrations are taken.

Interventions

None listed

Sponsors

St. Olavs Hospital
CollaboratorOTHER
Dr. Dedichens Institute for Psychiatric Research, Oslo, Norway.
CollaboratorUNKNOWN
GlaxoSmithKline
CollaboratorINDUSTRY
Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acutely admitted psychiatric patients who have at different times the last 2 weeks filled criteria for at least two new DSM-4 Axis 1 psychiatric diagnoses. One of them has to be a depressive episode (MADRS\>20)

Exclusion criteria

* Patients not speaking Norwegian or English. * Patients not willing to participate. * Patients with dementia or mental retardation to an extensive degree.

Design outcomes

Primary

MeasureTime frameDescription
epilepsy or an other organic brain disorder1 weekEEG and QEEG are taken three times in the first week

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026